Evidence map›Paper›PMID 36395068›Full record

ArticleBlood2023

FLT3ITD drives context-specific changes in cell identity and variable interferon dependence during AML initiation.

Yanan Li, Wei Yang, Riddhi M Patel, Emily B Casey, Elisabeth Denby, Jonny Mendoza-Castrejon, Priscilla Rodriguez-Lopez, Jeffrey A Magee

Open access · greenAbstract read
In one paragraph

Article in Blood, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. NovelCancers · 2023
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yanan LiDivision of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0003-4396-0557
Wei YangDepartment of Genetics, Washington University School of Medicine, St. Louis, MO.
Riddhi M PatelDivision of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-0169-1224
Emily B CaseyDivision of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO.
Elisabeth DenbyDivision of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO.
Jonny Mendoza-CastrejonDivision of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0001-9558-152X
Priscilla Rodriguez-LopezDivision of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO.
Jeffrey A MageeDivision of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-0766-4200
Washington University in St. Louis · US

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0M
MOLECULAR ONCOLOGY TRAINING GRANTT32CA113275 · NCI · WASHINGTON UNIVERSITY · PI Matthew J Walter · 2006 to 2026
$5.7M
The role of Kmt2c/MLL3 in hematopoietic stem cell self-renewal, commitment and exhaustionR01HL152180 · NHLBI · WASHINGTON UNIVERSITY · PI Jeffrey Alan Magee · 2020 to 2026
$3.0M
The influence of proteostasis loss in aging hematopoietic stem cells on leukemia initiationU01CA267031 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MAGEE, JEFFREY ALAN, SIGNER, ROBERT A.J. · 2021 to 2025
$2.0M
TEMPORAL CHANGES IN MECHANISMS OF HSC SELF-RENEWAL AND MYELOID LEUKEMOGENESISR01HL136504 · NHLBI · WASHINGTON UNIVERSITY · PI MAGEE, JEFFREY ALAN · 2017 to 2021
$1.9M
NCI NIH HHS P30 CA091842NCI NIH HHS T32 CA113275NCI NIH HHS U01 CA267031NHLBI NIH HHS R01 HL136504NHLBI NIH HHS R01 HL152180
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) initiation requires multiple rate-limiting mutations to cooperatively reprogram progenitor cell identity. For example, FLT3 internal tandem duplication (FLT3ITD) mutations cooperate with a variety of different initiating mutations to reprogram myeloid progenitor fate. These initiating mutations often skew toward either pediatric or adult AML patient populations, though FLT3ITD itself occurs at similar frequencies in both age groups. This raises the question of whether FLT3ITD might induce distinct transcriptional programs and unmask distinct therapeutic vulnerabilities when paired with pediatric, as opposed to adult AML-initiating mutations. To explore this possibility, we compared AML evolution in mice that carried Flt3ITD/NUP98-HOXD13 (NHD13) or Flt3ITD/Runx1DEL mutation pairs, which are respectively most common in pediatric and adult AML. Single-cell analyses and epigenome profiling revealed distinct interactions between Flt3ITD and its cooperating mutations. Whereas Flt3ITD and Flt3ITD/Runx1DEL caused aberrant expansion of myeloid progenitors, Flt3ITD/NHD13 drove the emergence of a pre-AML population that did not resemble normal hematopoietic progenitors. Differences between Flt3ITD/Runx1DEL and Flt3ITD/NHD13 cooperative target gene expression extended to fully transformed AML as well. Flt3ITD/NHD13 cooperative target genes were enriched in human NUP98-translocated AML. Flt3ITD/NHD13 selectively hijacked type I interferon signaling to drive expansion of the pre-AML population. Blocking interferon signaling delayed AML initiation and extended survival. Thus, common AML driver mutations, such as FLT3ITD, can coopt different mechanisms of transformation in different genetic contexts. Furthermore, pediatric-biased NUP98 fusions convey actionable interferon dependence.

Indexed as

InterferonsLeukemia, Myeloid, AcuteAnimalsChildfms-Like Tyrosine Kinase 3HumansMiceMutationSignal TransductionTranscription Factorsfms-Like Tyrosine Kinase 3InterferonsTranscription Factors

Identifiers

PMID36395068
PMCPMC10082380
OpenAlexW4309218773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.